cytosine has been researched along with Hematologic Diseases in 9 studies
Hematologic Diseases: Disorders of the blood and blood forming tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Therapeutic effectiveness of 5-fluorocytosine (5-FC), amphotericin B (Am B) and both in combined administration were retrospectively assessed and compared with one another in 28 patients with cryptococcal meningitis." | 9.04 | Comparison between 5-fluorocytosine, amphotericin B and the combined administration of these agents in the therapeutic effectiveness for cryptococcal meningitis. ( Ikemoto, H; Jimbow, T; Tejima, Y, 1978) |
| "In a prospective study from May 1971 to November 1973, 20 consecutive patients with a diagnosis of disseminated cryptococcosis were treated for six weeks with a combination of amphotericin B (20 mg daily) intravenously and flucytosine (150 mg/kg daily) orally." | 7.65 | Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. ( Duma, RJ; Garriques, IL; Mandell, GL; McGehee, RF; Sande, MA; Shadomy, S; Utz, JP; Warner, JF, 1975) |
| "Therapeutic effectiveness of 5-fluorocytosine (5-FC), amphotericin B (Am B) and both in combined administration were retrospectively assessed and compared with one another in 28 patients with cryptococcal meningitis." | 5.04 | Comparison between 5-fluorocytosine, amphotericin B and the combined administration of these agents in the therapeutic effectiveness for cryptococcal meningitis. ( Ikemoto, H; Jimbow, T; Tejima, Y, 1978) |
| "In a prospective study from May 1971 to November 1973, 20 consecutive patients with a diagnosis of disseminated cryptococcosis were treated for six weeks with a combination of amphotericin B (20 mg daily) intravenously and flucytosine (150 mg/kg daily) orally." | 3.65 | Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. ( Duma, RJ; Garriques, IL; Mandell, GL; McGehee, RF; Sande, MA; Shadomy, S; Utz, JP; Warner, JF, 1975) |
| " Eight patients were enrolled on a dosage schedule of 1 mg/kg 3 times weekly." | 2.70 | Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. ( Hoffman, JA; Kapoor, N; Ross, LA; Shah, AJ, 2001) |
| " After treatment on the fifth day, terminal half-life values averaged 39 (63) hours, and Cl(s) was reduced by approximately 20%, averaging 127 (27) mL/min." | 2.70 | Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. ( Baker, SD; de Bono, JS; Goetz, A; Hammond, LA; Hidalgo, M; Jolivet, J; Patnaik, A; Rowinsky, EK; Simmons, C; Siu, L; Stephenson, J; Weiss, G, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| An, J | 1 |
| Ko, M | 1 |
| Herrlinger, U | 1 |
| Schwärzler, F | 1 |
| Beck, R | 1 |
| Küker, W | 1 |
| Hebart, H | 1 |
| Kanz, L | 1 |
| Dichgans, J | 1 |
| Weller, M | 1 |
| Auré, K | 1 |
| Béhin, A | 1 |
| Louillet, F | 1 |
| Lafitte, C | 1 |
| Sanson, M | 1 |
| Vernant, JP | 1 |
| Witte, S | 1 |
| Goldenberg, DM | 1 |
| Santini, V | 1 |
| Kantarjian, HM | 1 |
| Issa, JP | 1 |
| Hoffman, JA | 1 |
| Shah, AJ | 1 |
| Ross, LA | 1 |
| Kapoor, N | 1 |
| de Bono, JS | 1 |
| Stephenson, J | 1 |
| Baker, SD | 1 |
| Hidalgo, M | 1 |
| Patnaik, A | 1 |
| Hammond, LA | 1 |
| Weiss, G | 1 |
| Goetz, A | 1 |
| Siu, L | 1 |
| Simmons, C | 1 |
| Jolivet, J | 1 |
| Rowinsky, EK | 1 |
| Jimbow, T | 1 |
| Tejima, Y | 1 |
| Ikemoto, H | 1 |
| Utz, JP | 1 |
| Garriques, IL | 1 |
| Sande, MA | 1 |
| Warner, JF | 1 |
| Mandell, GL | 1 |
| McGehee, RF | 1 |
| Duma, RJ | 1 |
| Shadomy, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Decitabine for COVID-19 Pneumonia-ARDS Treatment: DART Trial[NCT04482621] | Phase 2 | 33 participants (Actual) | Interventional | 2020-09-14 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for cytosine and Hematologic Diseases
| Article | Year |
|---|---|
Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation.
Topics: 5-Methylcytosine; Animals; Cell Differentiation; Cell Transformation, Neoplastic; Cytosine; Dioxygen | 2023 |
Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.
Topics: 5-Methylcytosine; Acetylation; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Tr | 2001 |
3 trials available for cytosine and Hematologic Diseases
| Article | Year |
|---|---|
Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation.
Topics: Adenoviridae Infections; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Cidofovir; Cy | 2001 |
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytosine; Dioxolanes; Dose-Response Relations | 2002 |
Comparison between 5-fluorocytosine, amphotericin B and the combined administration of these agents in the therapeutic effectiveness for cryptococcal meningitis.
Topics: Adult; Aged; Amphotericin B; Clinical Trials as Topic; Cryptococcosis; Cytosine; Drug Administration | 1978 |
4 other studies available for cytosine and Hematologic Diseases
| Article | Year |
|---|---|
Progressive multifocal leukoencephalopathy: cidofovir therapy in three patients with underlying hematological disease.
Topics: Aged; Cidofovir; Cytosine; Hematologic Diseases; Humans; Leukoencephalopathy, Progressive Multifocal | 2003 |
Dramatic improvement in non-AIDS related progressive multifocal leucoencephalopathy.
Topics: Antiviral Agents; Cidofovir; Cytarabine; Cytosine; Drug Therapy, Combination; Hematologic Diseases; | 2005 |
[First clinical studies with the antimetabolite cytosine arabinoside in chemotherapy of hemoblastoses and related diseases].
Topics: Blood Cell Count; Cytosine; Glycosides; Hematologic Diseases; Hodgkin Disease; Humans; Lymphoma, Non | 1967 |
Therapy of cryptococcosis with a combination of flucytosine and amphotericin B.
Topics: Adult; Aged; Amphotericin B; Cryptococcosis; Cytosine; Drug Therapy, Combination; Female; Flucytosin | 1975 |